Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 4/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SOD1 | P00441 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5540013 | 0.90 | ALDH3A1 (0.50) | ALDH3A1DRD4DRD2DRD3KCNH2 | |
| SCHEMBL5534926 | 0.88 | ALDH3A1 (0.53) | ALDH3A1DRD4DRD2DRD3KCNH2 | |
| SCHEMBL5539527 | 0.86 | ALDH3A1 (0.51) | ALDH3A1DRD4DRD2DRD3KCNH2 | |
| SCHEMBL1345118 | 0.79 | MAOB (0.57) | ALDH3A1DRD4DRD2DRD3KCNH2 | |
| SCHEMBL9415981 | 0.79 | LTA4H (0.50) | DRD4DRD2DRD3CYP1A2CYP2C19 | |
| SCHEMBL7352169 | 0.79 | NQO1 (0.58) | L3MBTL1NPC1SMN1; SMN2MEN1TSHR | |
| SCHEMBL98739 | 0.79 | KDM4E (0.44) | DRD4DRD2DRD3L3MBTL1MEN1 | |
| SCHEMBL21052116 | 0.79 | L3MBTL1 (0.53) | DRD4DRD2DRD3KCNH2L3MBTL1 | |
| SCHEMBL8415070 | 0.79 | GAA (0.58) | ALDH3A1DRD4DRD2DRD3KCNH2 | |
| SCHEMBL7345979 | 0.79 | TDP1 (0.50) | L3MBTL1NPC1RAB9ASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5221746-A | Inhibitors of visna virus; treatment of AIDS and ARC | G. D. SEARLE & CO. (US) | 1993-06-22 | — | — | US | claimed |
| EP-0494850-A2 | Novel antiviral compounds | G.D. Searle & Co. (US) | 1992-07-15 | — | — | EP | claimed |
| EP-2473493-B1 | METHODS OF TREATING POXVIRAL INFECTIONS | UNITED THERAPEUTICS CORP (US) | 2014-04-30 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-6043226-A | TREATING BACTERIAL, PARASITIC AND PROTOZOAL INFECTIONS | PFIZER INC. (US) | 2000-03-28 | — | — | US | disclosed |
| US-5476859-A | Inhibiting lentivirus by orally administering derivatives of 1,5-dideoxy-1,5-imino-D-glucitol | PARTIS RICHARD A (US) | 1995-12-19 | — | — | US | disclosed |
| US-5411970-A | Method of inhibiting lentivirus | G. D. SEARLE & CO. (US) | 1995-05-02 | — | — | US | disclosed |
| US-5310745-A | Acylated derivatives of 1,5-dideoxy-1,5-imino-D-glucitol, AIDS | G. D. SEARLE & CO. (US) | 1994-05-10 | — | — | US | disclosed |
| US-5221746-A | Inhibitors of visna virus; treatment of AIDS and ARC | G. D. SEARLE & CO. (US) | 1993-06-22 | — | — | US | disclosed |
| US-5221746-A | Inhibitors of visna virus; treatment of AIDS and ARC | G. D. SEARLE & CO. (US) | 1993-06-22 | — | — | US | disclosed |
| US-5144037-A | Viricides | G. D. SEARLE & CO. (US) | 1992-09-01 | — | — | US | disclosed |
| US-5144037-A | Viricides | G. D. SEARLE & CO. (US) | 1992-09-01 | — | — | US | disclosed |
| EP-0494850-A2 | Novel antiviral compounds | G.D. Searle & Co. (US) | 1992-07-15 | — | — | EP | disclosed |
| EP-0494850-A2 | Novel antiviral compounds | G.D. Searle & Co. (US) | 1992-07-15 | — | — | EP | disclosed |
| EP-0094348-B1 | OXIME ETHERS, PROCESS FOR THEIR PREPARATION, AGENTS CONTAINING THE OXIME ETHERS AND THEIR USE | CIBA-GEIGY AG (CH) | 1985-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ALDH3A1 98/4885DRD4 368/4885DRD2 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.